In their March 2006 report, the Institute of Medicine (IOM) showed overwhelming evidence of the existence of health related disparities for racial and ethnic minorities. The reports definition of cancer health related disparities refers to the unequal treatment of patient population groups the difference in treatment or access not justified by the differences in health status or preferences of the groups on the basis of race, ethnicity, and sometimes on the basis of gender, socioeconomic status, age or other patient characteristics.[1]
Over the last decade multiple medical societies and governmental agencies have studied the cause of cancer health disparities as well as attempted to identify solutions to the problem.
Five different studies being presented during the 61st annual meeting of the American Society of Hematology (ASH), held December 7 10, 2019 in Orlando, Florida, paint a mixed portrait of how demographics and socioeconomic status affect access to clinical trials and effective treatments for patients with blood cancers.
Some studies show encouraging evidence that racial minorities and older patients receive similar benefits compared to cancer treatments other patient groups receive. However, other studies show that their are still significant gaps in terms of care access and outcomes, underscoring the urgent need for renewed efforts to address disparities.
Inclusion is not only the right thing to do for our patients and our community its also the right thing to do if our goal is to create medicines that are truly targeted, noted Laura Michaelis, MD, Medical College of Wisconsin.
Clinical trialsBut the studies go beyond traditional healthcare. What is, for example, the impact of clinical trial inclusion criteria on cancer health disparities?
Based on data from a number of clinical trials, inclusion and exclusion criteria can become too restricting, limiting patient access. Other studies demonstrate that some of these criteria may result in the systematic exclusion minorities and older patients.
Our ability to achieve tailored treatments and prevention relies on including a wide and heterogeneous spectrum of individuals in clinical trials, Michaelis noted.
We have an obligation to recruit people who are traditionally absent from trials, including groups such as women, older people, minorities, people living in poverty, and people who are chronically ill or who have comorbidities, she concluded.
Socioeconomic Disparities in Survival of ChildrenA study by Lena E. Winestone, MD, MSHP and colleagues, at UCSF Benioff Childrens Hospital in San Francisco, shows that children from poorer neighborhoods were 2.4 times more likely to die during treatment for acute myeloid leukemia or AML than children from middle and high-income neighborhoods. [2]
The results of the study, funded by National Institutes of Health/National Cancer Institute (NIH/NCI), are based on an analysis of nearly 1,500 clinical trial participants. While previous research has pointed to racial disparities in cancer survival, the new study is the first to identify socioeconomic status as a key contributor to disparities among children with AML who were enrolled in clinical trials.
These findings are especially alarming because clinical trials are designed to provide consistent treatment across all participant groups. The fact that disparities were found despite the rigorous setting of clinical trials suggests that these disparities arise from a variety of factors outside of the specific chemotherapeutic therapy used.
We expected there to be a difference, but the degree of difference is quite substantial, Winestone, who is the lead study author, noted.
The more people are cognizant about the disparities that exist, the better positioned well be to ameliorate them, he added.
Researchers at UCSF Benioff Childrens Hospital and the Childrens Hospital of Philadelphia examined clinical trial data from children enrolled on two recent AML trials, AAML1031/NCT01371981 and AAML0531/NCT01407757, and used U.S. Census data to determine the median income and educational attainment in patients neighborhoods. [2]
They found that neighborhood socioeconomic factors were significant predictors of survival, even after accounting for insurance type, race, and known biologic risk factors.
While about 68% of patients from middle or high-income areas survived for five years following diagnosis, that proportion was 61% among patients from low-income areas and just 43% among patients living in poverty.
A significantly higher proportion of Black and Hispanic patients lived in poverty, low income, and low education areas. Researchers found that the racial disparity persisted even after accounting for neighborhood socioeconomic factors, suggesting Black patients face a significantly higher risk of death than white children living in areas of the same socioeconomic level.
The study did not determine the reasons behind the increased risk of death.
However, Winestone noted that one possibility is that toxic stress, which has been linked with lower socioeconomic status, may impact responses to chemotherapy or immune recovery following chemotherapy.
The researchers plan to further examine when patients died and the cause of death in the hopes of gaining insights as to whether the risks are connected to treatment-related causes or to the cancer itself.
Winestone also pointed out that in addition to drawing attention to persistent racial and socioeconomic disparities in cancer outcomes, the results also highlight potential additional data to be collected as part of clinical trials.
Rather than relying on neighborhood data as a proxy, she explained, it would be helpful if future clinical trials collected individual data on participants socioeconomic status at the time of enrollment.
If we could gather that information, it would allow us to dig deeper into the question of how someones circumstances outside of the clinical aspects of their disease impact their health outcomes, Winestone concluded.
Racial Disparities and comorbidities and/or organ dysfunctionA study of more than 1,000 patients with AML revealed that African Americans were more likely to have evidence of abnormal kidney functioning than whites, but this was not associated with any difference in overall survival. [3]
The findings have implications for the design of clinical trials, which typically exclude patients with signs of kidney dysfunction and may, as a result, disproportionately, and unnecessarily, exclude minorities from participating in clinical trials.
Its important that we understand how drugs work in different patient populations in clinical trials, especially those that reflect the patients we will eventually treat with the drug, said lead study author Abby Statler, Ph.D, of Cleveland Clinic.
Designers of clinical trials can use data from studies like ours to inform future eligibility criteria in order to test drugs in more diverse populations, Statler further noted.
Clinical trials test the effectiveness of new treatments and identify any safety concerns before a drug can be sold on the market. Trials often seek to enroll patients who have only a few health problems (called comorbidities)other than the one being studied. This approach makes it easier to tell if study outcomes are related to the use of the experimental drug rather than influenced by a patients other health conditions or medications. However, because patients in racial minorities may, on average, have more comorbidities, this practice may disproportionately exclude these individuals from clinical trials. As a result, the population of trial participants does not reflect the real-world diversity of the patient population who will ultimately receive the investigational drug following regulatory approval.
In this study, researchers examined health records from 1,040 AML patients receiving care at Cleveland Clinic from 2003-2019. They found no significant differences between African American and white patients in treatment approaches, rates of responsiveness to treatment, or overall survival, suggesting that treatments worked just as well in African Americans as whites.
However, the study demonstrated that African Americans were significantly more likely to have abnormal creatinine and creatinine clearance, signs that the kidneys are not clearing waste products from the bloodstream as effectively as they should. However, this abnormality may be benign, as previous studies suggest African Americans have higher creatinine levels than whites. Consequently, this laboratory value may falsely underestimate this subpopulations kidney function, causing them to fail study enrollment requirements that require normal creatinine or creatinine clearance values.
The researchers observed that patients with minor creatinine or creatinine clearance abnormalities showed no differences in overall survival. This, they noted, calls into question the necessity of excluding patients with these abnormalities from AML trials.
The study, Statler noted, also bolstered evidence that African Americans may simply have higher baseline creatinine levels than white patients.
These findings suggest trials might be able to broaden their criteria to include patients with kidney disease without compromising the safety of the participants, said Statler.
In doing so, we might be able to truly improve the number of patients from minority populations who are potentially eligible for trials but who would have been excluded for that reason alone, she said.
The study also examined markers for a variety of comorbidities including endocrine, gastrointestinal, liver, cardiovascular, and neurological functioning. Of these, liver dysfunction was the only comorbidity that was associated with diminished survival. The researchers plan to further examine the data to determine precise kidney function cutoff points for future clinical trial eligibility criteria.
Statler concluded that in addition to AML the study findings could be relevant to designing trials for other cancers, particularly prostate cancer, which disproportionately affects African American men.
A Hands-On ApproachA study of 182 patients treated for diffuse large B-cell lymphoma (DLBCL) at a safety net cancer center reports that non-white patients had similar health outcomes to white patients. The findings contrast previous population-based studies pointing to racial disparities in lymphoma outcomes and suggest possible steps tertiary centers can take to help close the gap. [4]
Researchers at the Levine Cancer Institute study found no significant differences between racial groups in terms of overall survival or survival without disease progression at two years. Racial groups also had similar rates of relapse, stem cell transplantation, and clinical trial enrollment. While the study does not indicate a specific reason for the lack of disparities, researchers suggest historically underserved patients may have benefited from hands-on assistance through the institutions patient navigator program, which was used by 85% of patients in the study.
The scientific literature shows that racial minorities tend to have poorer outcomes in lymphoma and several other diseases, and we wanted to know if that holds true at our institution, said senior study author Nilanjan Ghosh, MD, Ph.D, of Levine Cancer Institute.
We found that minorities do not have worse outcomes for DLBCL if the disease is optimally managed, which requires that all patients have access to care. It shows that if you work on addressing socioeconomic barriers, you can get equal results.
The centers patient navigator program is designed to help patients address logistical barriers to keeping appointments and staying on track with their cancer treatment.
For example, navigators can help patients who are homeless take advantage of lodging that is available for patients undergoing cancer treatment. They can also help arrange transportation for patients without a car. And navigators can help coordinate care across providers such as primary care physicians, oncologists, and other specialists.
Analyzed data related to patients treated for newly diagnosed DLBCL between 2016-2019, the researchers noted that about four out of five patients identified themselves as white. On average, 73% of non-white patients identifying themselves as African American and 15% identified as Hispanic.
White patients were significantly more likely to have private health insurance and less likely to have government insurance or no insurance than non-whites. In addition, white patients were slightly older than non-white patients.
Despite the differences in health insurance type, the researchers also found that white and non-white had similar rates of overall survival (74% and 81%, respectively) two years after diagnosis, as well as similar rates of progression-free survival (60% and 63%, respectively). Treatment regimens and outcomes for those with relapsed or refractory DLBCL were, according to the researchers, also similar among groups.
Age Should Not Be a BarrierEven though autologous hematopoietic cell transplantation (AHCT), a form of stem cell therapy, is an effective treatment for multiple myeloma, only four out of 10 patients receive this therapy. A new study by Anita DSouza, MD, Medical College of Wisconsin, and colleagues demonstrated that AHCT is safe and effective in older patients and suggests that more people could benefit from the therapy than have typically been offered it. [5]
Older people are often excluded from clinical trials studying transplant because they tend to have a greater number of health issues. Without trials proving newer, aggressive treatments are safe for older patients, doctors may avoid them on the assumption that they are too risky. In addition to showing AHCT is safe and effective in patients over 70 years of age. The researchers also found patients fared better when given the conditioning chemotherapy drug melphalan (Alkeran) in the normal dose of 200 mg/m2, rather than the reduced dose of 140 mg/m2 often given to older patients.
This study shows that you can perform these transplants safely in older patients, and the older patients get the same benefits from these treatments as the younger patients do, DSouza, who is the studys lead author, noted.
In addition, if there are no contraindications other than simply age, its worth trying the higher dose of melphalan. Age alone should not be a reason to automatically reduce the dose, DSouza added.
According to DSouza, the study strengthens the argument that people should not just be excluded from clinical trials based on age alone. Multiple myeloma is the second most common blood cancer, and it occurs most often in older adults. Half of patients are age 70 or older at the time of diagnosis.
Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, the researchers examined health records of approximately 16,000 patients who received AHCT with melphalan in the United States between 2013-2017.
After adjusting for factors such as functional status, comorbidities, and disease stage, they found patients who received their treatments at age 70 or older had similar rates of relapse or disease progression, progression-free survival, and death not caused by a cancer relapse as those 60-69 years of age.
Of patients age 70 and older, about 40% received the full dose of melphalan and 60% received a reduced dose. Those receiving the reduced dose had significantly worse outcomes and lower survival rates. However, DSouza noted that it is impossible to determine whether these patients were also more frail to begin with, in which case their poorer outcomes would not necessarily be due to the dosing reduction.
While AHCT specialists often support the use of AHCT in otherwise healthy older patients, DSouza noted that oncologists in community hospitals where many patients are first treated often fail to refer older patients to transplant centers. The researchers noted a significant increase in the proportion of older patients receiving AHCT in 2017 compared to 2013, suggesting that referrals to AHCT specialists increased over time.
In addition to age disparities, the study also speaks to important racial disparities in the care of patients with myeloma, a disease which is twice as common in African Americans as whites. Yet AHCT rates are significantly lower among black patients, which made DSouza concluded that age likely adds to the barriers for these patients.
CAR T-cell therapy Reduces Health Care Utilization in Older PatientsA new analysis of Medicare claims data offers the first real-world evidence using claims data available after the approval of autologous anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy. [6]
These analyses, Karl M. Kilgore, Ph.D, of Avalere Health observed, shows that CAR T-cell therapy may be beneficial for a broad population of older patients with DLBCL, including those with multiple chronic conditions. The research also shows patients spent less time in the hospital and had lower health care costs after CAR T-cell therapy than they did in the months leading up to it.
The U.S. Food and Drug Administration (FDA) approved the first CAR T-cell therapy for adults with DLBCL in 2017. However, many of the patients included in the clinical trials leading up to that approval were middle-aged, with a median age of 56-58. This study used the earliest available Medicare claims data to assess the treatments use in Medicare patients age 60 and older, who comprise the majority of Medicare beneficiaries and often have multiple chronic health issues.
Our findings offer evidence that older patients with multiple comorbidities can be treated successfully with CAR T-cell therapy, Kilgore, who is the lead study author, said.
While we dont know the long-term outcomes yet, nearly three-quarters of the patients were still alive six months post-treatment. Even in that narrow window of time we saw a significant decline in health care utilization including hospitalizations and emergency room use, which is suggestive of a successful course of treatment, Kilgore concluded.
DLBCL, a cancer that starts in the white blood cells, accounts for about one-third of the 74,000 cases of non-Hodgkin lymphoma diagnosed in the United States each year. About 63% of patients survive for five years after their diagnosis. For those who relapse or have refractory disease, treatment options include chemotherapy, stem cell transplantation, and CAR T-cell therapy. CAR-T works by re-engineering a patients own T-cells, part of the immune system, to kill cancer cells. Multiple steps are required to collect, modify, and re-infuse T-cells into the patient, a process that is typically combined with lympho-depleting chemotherapy and a single infusion of the patients modified T-cells.
The researchers analyzed claims data from patients enrolled in Medicare Fee For Service parts A and B October 2017-September 2018. They identified 207 patients with an average age of 70 years who had undergone CAR T-cell therapy for DLBCL. Half underwent CAR T-cell therapy as part of a clinical trial, while the remainder had comorbidities that likely would have excluded them from CAR T-cell clinical trials.
Comparing health care utilization in the six months before and after CAR-T therapy, the researchers found patients average overall health care costs dropped by 39% after undergoing CAR-T, excluding the cost of the CAR-T treatment itself. In the months following CAR-T, patients spent less time in the hospital and had half as many emergency department visits than before the therapy.
Only 7.2% had any evidence of subsequent chemotherapy in the claims data, suggesting that the cancer had not returned within the first six months following CAR T-cell therapy for most patients.
Clinical trialsBortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01371981Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531 NCT01407757
Reference[1] McGuire TG, Alegria M, Cook BL, Wells KB, Zaslavsky AM. Implementing the Institute of Medicine definition of disparities: an application to mental health care. Health Serv Res. 2006;41(5):19792005. doi:10.1111/j.1475-6773.2006.00583.x [Abstract][2] Winestone LE, Getz KD, Bona KO, Fisher BT, Gamis AS, Seif AE, Sung L, Wang YC, Alonzo TA, and Aplenc R. Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Childrens Oncology Group. 61st annual meeting of the American Society of Hematology. Program: Oral and Poster Abstracts. Type: Oral Session: 906. Outcomes ResearchMalignant Conditions (Myeloid Disease): Quality of Life, Late Effects, and Prognostic Factors in Myeloid DiseasesHematology Disease Topics & Pathways: Diseases, AML, Pediatric, Study Population, Clinically relevant, Myeloid Malignancies. [Abstract][3] Statler A, Hobbs BP, Radivoyevitch T, Mukherjee S, Bell K, Advani AS, Gerds AT, Nazha A, Patel BJ, Carraway HE, and Sekeres MA. Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction? 61st annual meeting of the American Society of Hematology. Program: Oral and Poster Abstracts. Type: Oral Session: 903. Health Services ResearchMalignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies | Hematology Disease Topics & Pathways: Diseases, AML, Adult, Study Population, Myeloid Malignancies [Abstract][4] Hu B, Chen T, Boselli D, Bose R, JSymanowski JT, Raghavan D, Soni A, Park SI, Avalos BR, Copelan EA, Jacobs R, Ghosh N. Minorities Do Not Have Worse Outcomes for Diffuse Large B Cell Lymphoma (DLBCL) If Optimally Managed. 61st annual meeting of the American Society of Hematology. Program: Oral and Poster Abstracts. Type: Oral. Session: 905. Outcomes ResearchMalignant Conditions (Lymphoid Disease): Mountains Conquered, Challenges Remain: Survivorship and Disparities in the Hematologic Malignancies. Hematology Disease Topics & Pathways: Adult, Diseases, Non-Hodgkin Lymphoma, DLBCL, Study Population, Clinically relevant, Lymphoid Malignancies, Quality Improvement.[Abstract][5] Munshi PN, Hari P, Vesole DH, Jurczyszyn A, Zaucha J, Davila O, Kumar SK, Shah ND, Qazilbash MH, DSouza A. Breaking the Glass Ceiling of Age in Transplant in Multiple Myeloma. 61st annual meeting of the American Society of Hematology. Program: Oral and Poster Abstracts. Type: Oral Session: 731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation: Lymphoma and Plasma Cell Disorders | Hematology Disease Topics & Pathways: Adult, Study Population. [Abstract][6] Kilgore KM, Mohammadi I, Schroeder A, Teigland C, Purdum A, Shah GL. Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs. 61st annual meeting of the American Society of Hematology. Program: Oral and Poster Abstracts. Type: OralSession: 905. Outcomes ResearchMalignant Conditions (Lymphoid Disease): CAR T and Novel Therapies Coming of Age: Real-World and Patient-Centered Outcomes. Hematology Disease Topics & Pathways: Diseases, Biological, Therapies, CAR-Ts, Non-Hodgkin Lymphoma, DLBCL, Lymphoid Malignancies. [Abstract]
See the original post:
Addressing Disparities in Cancer: Factors Influencing Care, Access and Outcomes - OncoZine
